Purdue Research Foundation

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Mohamed S A Elsayed

Mark Stanley Cushman

Richard M Van Rijn

Markus Lill

Amr Hamed Mahmoud Abdallah

Robert J Cassell

Yves Pommier

Ping Wang

The present disclosure relates to novel &#x3b4;-opioid receptor agonists, and the method of making and using the novel &#x3b4;-opioid receptor agonists. The novel &#x3b4;-opioid receptor agonists are selective &#x3b4;-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel &#x3b4;-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.

Delta-opioid receptor agonists

Tyrosyl-DNA Phosphodiesterases 1 and 2 (Tdp1 and Tdp2) can repair damaged DNA resulting from topoisomerase inhibitors (e.g. Top1) and a variety of other DNA-damaging agents. 7-Azaindenoisoquinolines that are inhibitors of each of Top1, Tdp1 and Tdp2 are disclosed. Also described are methods for preparing azaindenoisoquinoline and methods for treating patients of a cancer using the disclosed azaindenoisoquinoline compounds or a pharmaceutical formulation thereof.

Azaindenoisoquinoline compounds and uses thereof

The invention described herein pertains to selective Janus kinase (JAK) inhibitors and methods of use thereof. Also described are methods for treating diseases involved abnormal JAK/STAT signaling pathway in mammals using the described selective JAK inhibitors or a pharmaceutical formulation thereof.

Janus kinase inhibitors and uses thereof

Growing community of inventors

West Lafayette, IN, United States of America

Mohamed S A Elsayed